Phase III Clinical Trial
The DIAS 4 Phase III clinical trial underway in Northwestern's Stroke Program is studying the effectiveness of intravenous thrombolytic (breaks up blood clots) desmoteplase administered in patients of acute ischemic stroke up to nine hours from stroke onset.
Currently, the only FDA-approved intravenous thrombolytic agent for acute ischemic stroke is alteplase (recombinant tissue plasminogen activator, or rtPA), to be administered within three hous of stroke onset.
What is DIAS 4?
The DIAS 4 study aims to confirm the safety and efficacy of desmoteplase for thrombolytic therapy in patients, extending the time window from three hours to nine hours after stroke onset.
This pivotal clinical trial extends the potential timetable for stabilization of patients with ischemic stroke for up to nine hours, representing a major clinical advance in the ability to treat this devastating disease.
If you would like to refer a patient with acute ischemic stroke, the Stroke Program at Northwestern would be pleased to:
- Accept the patient
- Assess them for enrollment in the DIAS 4 phase III clinical trial
- Consider other appropriate acute interventions
Click here if you would like to learn more about the DIAS 4 trial online.
Arrange a Transfer
To transfer a patient with stroke to Northwestern Memorial Hospital, please call the External Transfer phone line at 312-926-3321 and state that you are calling regarding a patient with an acute stroke. The on-call stroke attending neurologist will be contacted immediately to discuss your patient with you and arrange for transfer.
You may use this phone number for any patient with an acute cerebrovascular condition for whom transfer is desired.